Cookie-Richtlinie

Wir verwenden Cookies, um Informationen über die Leistung und Nutzung der Website zu erfassen und zu analysieren sowie um sicherzustellen, dass Ihre Navigation der Website erfolgreich verläuft. Wenn Sie rechts auf die Schaltfläche „Okay“ oder auf einen Inhalt auf der Website klicken, stimmen Sie damit dem Setzen von Cookies auf Ihrem Computer zu. Weitere Informationen finden Sie in unserer Datenschutzerklärung. 

 
Regionen
 
WEBSEITEN
  • United States (English)
  • International (English)
  • Chinesisch (中文)
  • Französisch (Français)
  • Deutsch
  • Italienisch (Italiano)
  • Japanisch (日本語)
  • Russisch (Русский)
  • Whole Blood Technologies
 

YesNo
  • Investor Relations
  • ANMELDEN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTRIEREN
  • Home
  • Produkte
     
    Internationale ProdukteUS-Produkte View U.S. Whole Blood Technologies
    Geräte
    OP- und Diagnosegeräte
    • Cell Saver 5+
    • Cell Saver Elite
    • SmartSuction Harmony
    • TEG
    Geräte für Blut- und Plasmazentren
    • ACP 215
    • MCS+
    • PCS 2
    Software
    Software für Blutspendezentren
    • Donor Doc
    • EdgeBlood
    • eDonor
    • Hemasphere
    Software für Krankenhäuser
    • EdgeLab
    • EdgeTrack
    Software für Plasmazentren
    • DonorDoc

    • EdgeBlood
    • eDonor

    • eLynx

    Serviceleistungen
    Softwareservices
    • Überblick über den Softwareservice
    • Kundenservice
    • Schulungen
    • Implementierungsservice
    • Technischer Service
    • Validierungsservice
     
  • Lösungen
     
    Blutmanagementlösungen
    • Lösungen für Blutspendezentren
    • Lösungen für Krankenhäuser
    • Lösungen für Plasmazentren
     
  • Infocenter
     
    Forschung und Publikationen
    • White Papers & Klinische Bewertungen (in Englisch)
    • Referenzlisten (in Englisch)
    • Poster-Abstracts (in Englisch)
    Schulungen
    • Präsentation
    Service Training
       
    • Über Haemonetics
       
      Das Unternehmen
      • Überblick
      • Unternehmensgeschichte
      • Führungsteam
      • Standorte
      Investor Relations
      • Investor Relations: Startseite
      • Informationen zur Aktie
      • Erträge
      • Prognosen & Leitlinien
      Neuigkeiten und Termine
      • Neuigkeiten
      • Terminkalender
      Stellenangebote
      • Stellenangebote – Überblick
      Grants 
         
      • Kundenservice

      YesNo
      • Home
      • Infocenter
      • Forschung und Publikationen
      • Poster-Abstracts (in Englisch)
      • Kontakt
      • Drucken
      • Teilen

      Poster-Abstracts (in Englisch)

      • AABB 2016

        Orlando, Florida

        • A novel approach for fat removal while maintaining blood quality in a discontinuous autotransfusion device - concept and evaluation
          Conclusions: Based on observations using a transparent centrifugation system, a hypothesis is presented to explain the accumulation of fat in the centrifuge bowl, both in spinning and stopped configurations. Modifications in process parameters and sequence resulted in the development of a dedicated fat removal program. This novel program significantly improves fat removal by the Latham bowl based autotransfusion device CS Elite, thus yielding results equivalent to the continuous autotransfusion system (CATS).
      • AABB 2012

        Boston, Massachusetts

        • Age of Blood Transfused In the United States: Data for 166,208 Transfusions
          Conclusions: For the hospitals studied, the current RBC supply chain and inventory management systems result in 47% of RBC units being transfused more than 3 weeks and 25% more than 4 weeks after their donation. Modifying the current supply chain to provide “fresher” blood will require substantial practice change and system redesign.
        • Blood Transfusion and Length of Stay: How Are They Related?
          Results: LOS was related to Nadir Hgb irrespective of transfusion status. Within each group of Nadir Hgb (except <7 g/dL), patients who received allogeneic blood had longer LOS than those who did not. Patients who received PAD (n=1179) had both longer LOS (3.50 vs. 3.07 days) and higher allogeneic transfusion rates (27.1% vs.17.3%) than those who did not receive PAD.
        • Variability in Transfusion Practice – Beyond Cardiac Surgery
          Methods: We queried a proprietary blood management business intelligence portal (IMPACT® Online, Haemonetics, Braintree, MA) and identified 9 noncardiac procedures associated with substantial red cell (RBC) transfusions. For each procedure, we determined the mean RBC transfusion and utilization rate for the entire hospital stay as well as the standard deviation (SD) of those rates among the participating hospitals (those that contributed at least 20 patients to each data set).
      • SABM 2012

        Pittsburgh, Pennsylvania

        • Periodic data review assures sustainability of blood management programs
          Results: Dramatic reductions in the use of PAD were achieved in each hospital. These improvements were not only sustained but continued during follow up. Similar success and sustainability was seen in the cardiac surgical interventions as reflected in decreased RBC utilization (units/patient including untransfused patients) for patients having coronary artery surgery (CABG).
        • Two unit dosing leads to excess transfusion
          Methods: Using a blood management business intelligence portal (IMPACT® Online, Haemonetics®, Braintree, MA) we determined the hematocrit at discharge of transfused patients who had either unilateral total hip or knee replacements during 2010 or 2011. From a group of 20,758 patients at 15 US hospitals, we removed 105 with incomplete data, 545 without a hematocrit following their last transfusion and 1,194 who received preoperatively donated autologous blood. Of the remaining 18,914, 3,033(16%) received allogeneic RBC.
      • Poster Archives

        Click here to view posters from previous years.
      • Kontakt
      • Nutzungsbedingungen
      • Qualität
      • Datenschutzerklärung
      • Inhaltsübersicht

      © 2011-2019 Haemonetics Corporation